CORNERSTONE THERA (NASDAQ:CRTX)
5.96
+0.19 (3.29%)
| CORNERSTONE THERA (NASDAQ:CRTX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $5.77 | 52 Week High | $12.29 | ||
| Open | $5.77 | 52 Week Low | $0.39 | ||
| Day High | $6.05 | P/E | 2.75 | ||
| Day Low | $5.77 | EPS | $2.17 | ||
| Volume | 15,393 | ||||
| More CRTX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ALKS | 1 | AHT | 1 |
| CKP | 1 | EQY | 1 |
| HEES | 1 | LLNW | 1 |
| NSYS | 1 | ROCK | 1 |
| TRP | 1 | FPP | 1 |
| ARJ | 1 | CWEI | 1 |
Entities who have mentioned CRTX
- Life, Style and Real Estate | View Related Stories »
- Bankruptcy | View Related Stories »
- Federal Open Market Committee | View Related Stories »
- Crude Oil | View Related Stories »
- Trading Radar | View Related Stories »
- Layoffs | View Related Stories »
- Vanguard | View Related Stories »
- Lazard | View Related Stories »
- Piper Jaffray | View Related Stories »
- Citi | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- ADP Employment Report | View Related Stories »
View All Major News StreetInsider.com Major News for CRTX
- Cornerstone Thera (CRTX) Posts Q3 EPS of $0.07, Beats By 6c; Guides FY09 Revs Higher
- Cornerstone Therapeutics (CRTX) Reports FY08 EPS of $1.14; Guides FY09 Sales
View All ReportsStreetInsider.com Reports on CRTX
- Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA
- Cornerstone Thera (CRTX) Posts Q3 EPS of $0.07, Beats By 6c; Guides FY09 Revs Higher
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Cornerstone Therapeutics (CRTX) Receives Approval to Acquire Commercial Rights to the Antibiotic Factive
- Cornerstone Therapeutics (CRTX) Submits Regulatory Filing for Extended-Release Antitussive Product
View All Press ReleasesCompany Press Releases on CRTX
- Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
- Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
- Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
- Cornerstone Therapeutics Appoints General Counsel
- Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results
StreetInsider Reports on CRTX by Category
View All BlogsBlogs on CRTX
- FDA Calendar Updates: Zogenix, Aradigm, Medtronic, BioForm, Cornerstone
- Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
- Where Might Genentech Investors Redeploy $47B?
View All FilingsSEC Filings on CRTX
- Form 8-K CORNERSTONE THERAPEUTICS For: Nov 11
- Form 10-Q CORNERSTONE THERAPEUTICS For: Sep 30
- Form 8-K CORNERSTONE THERAPEUTICS For: Nov 04
- Form 4 Powell Andrew Kenneth For: Oct 30
- Form 8-K CORNERSTONE THERAPEUTICS For: Oct 13
Comments on recent CRTX articles
Comments on CRTX
No comments are currently available.
on May 10, 2009
at 05:36 PM crtx well managed Their pulmonary drugs are outstanding and reliable.
Article: Cornerstone Therapeutics (CRTX) Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA